TrialPloS one2016

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.

Christoph Sarrazin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.